Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Associated Therapies: -

Clinical Trials

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2008-01-18

Last Posted Date: 2023-05-17

Lead Sponsor: Rush University Medical Center

Target Recruit Count: 11

Registration Number: NCT00597597

Locations: 🇺🇸
Rush University Medical Center Division of Hematology/Oncology, Chicago, Illinois, United States

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: XL184
Drug: erlotinib

First Posted Date: 2008-01-17

Last Posted Date: 2013-09-19

Lead Sponsor: Exelixis

Target Recruit Count: 92

Registration Number: NCT00596648

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Georgetown University/Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
Park Nicollet Institute, St. Louis Park, Minnesota, United States

and more 10 locations

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

Phase 2

Completed

Conditions: Unresectable Adenocarcinoma of the Esophagus
Metastatic Adenocarcinoma of the Esophagus
Metastatic Adenocarcinoma of Gastric Cardia
Unresectable Adenocarcinoma of Gastric Cardia

Interventions: Drug: FOLFOX
Drug: 5-FU
Drug: Erlotinib

First Posted Date: 2008-01-11

Last Posted Date: 2021-10-01

Lead Sponsor: Translational Oncology Research International

Target Recruit Count: 38

Registration Number: NCT00591123

Locations: 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Translational Oncology Research International (TORI) Network, Los Angeles, California, United States

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Phase 1

Conditions: Advanced Solid Tumors

Interventions: Drug: indibulin
Drug: erlotinib

First Posted Date: 2008-01-11

Last Posted Date: 2012-07-19

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 10

Registration Number: NCT00591383

Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

Phase 2

Completed

Conditions: Lung Cancer
Non Small Cell Lung Cancer

Interventions: Drug: erlotinib
Drug: Pemetrexed
Drug: Cisplatin
Procedure: Resection

First Posted Date: 2007-12-20

Last Posted Date: 2018-01-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT00577707

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: erlotinib
Drug: RAD001

First Posted Date: 2007-12-17

Last Posted Date: 2016-05-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 14

Registration Number: NCT00574366

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Placebo
Drug: erlotinib

First Posted Date: 2007-12-10

Last Posted Date: 2021-03-30

Lead Sponsor: University of Arkansas

Target Recruit Count: 27

Registration Number: NCT00570258

Locations: 🇺🇸
Hackensack University, Hackensack, New Jersey, United States
🇺🇸
St. Luke's Cancer Institute, Kansas City, Missouri, United States
🇺🇸
NEA Clinic, Jonesboro, Arkansas, United States

and more 3 locations